Led by investigators of the Vall d'Hebron Institute of Oncology's (VHIO) Experimental Therapeutics Group, in collaboration with VHIO's Hereditary Cancer Genetics Group and the Medical Oncology Department at the Vall d'Hebron ...
Sep 3, 2024
0
35
The anti-cancer drug olaparib may be effective in treating biochemically recurrent prostate cancer without accompanying hormone therapy for men who have mutations in genes such as BRCA2, according to results of a Phase II ...
Aug 22, 2024
0
38
Two-thirds of the public say they are very or somewhat worried about being told they have the disease—higher than for any other medical condition, including dementia and having a heart attack—according to polling.
Jul 14, 2024
0
60
A new drug could offer a powerful way to sensitize tumors to immunotherapy, a new trial suggests. The results have been published in the Journal of Clinical Investigation.
Feb 27, 2024
0
53
A specific combination of targeted therapy and immunotherapy may better help patients with non-small cell lung cancer (NSCLC) overcome inherent immune resistance and reinvigorate anti-tumor activity, according to a new study ...
Feb 13, 2024
0
50
Men with hormone-resistant prostate cancer and specific genetic mutations who were treated with the PARP inhibitor drug olaparib survived longer than men treated with traditional hormone therapy, according to an analysis ...
Dec 7, 2023
0
38
Immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab improved progression-free survival (PFS) in patients with newly diagnosed advanced or recurrent endometrial cancer compared with chemotherapy alone, with further ...
Oct 23, 2023
0
42
New research, published in Nature Genetics, shows that more people may benefit from PARP inhibitor drugs, like olaparib, which are already used to treat some breast, ovarian and prostate cancer patients who have inherited ...
Aug 1, 2023
0
71
The U.S. Food and Drug Administration approved Lynparza (olaparib) with abiraterone and prednisone (or prednisolone) for adult patients with deleterious or suspected deleterious BRCA-mutated, metastatic, castration-resistant ...
Jun 7, 2023
0
69
In the five years since the FDA's initial approval of chimeric antigen receptor (CAR) T cell therapy, Penn Medicine has gleaned 20 additional approvals related to drugs and techniques to treat or detect cancer.
May 29, 2023
0
106
